EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)

Akira Shimatsu, Beverly Mk Biller, Maria Fleseriu, Rosario Pivonello, Eun Jig Lee, Rattana Leelawattana, Jung Hee Kim, Rama Walia, Yerong Yu, Zhihong Liao, Andrea Piacentini, Alberto M Pedroncelli und 1 weitere

Endocrine Journal · 2024 · 71 (12) · 1103-1123

DOI: 10.1507/endocrj.ej24-0153 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Endocrine Journal, 2024. Verfasst von Akira Shimatsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Omi Medical Center, Kusatsu 525-8585, Japan. Hauptthemen laut MEDLINE: Pituitary ACTH Hypersecretion, Asian People. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary ACTH HypersecretionAsian PeopleHumansMaleFemaleAdultMiddle AgedTreatment OutcomeHydrocortisoneAgedYoung AdultImidazolesPyridines

Stichwörter der Autor:innen

Clinical trialCushing’s syndromeEfficacyRaceSafety

Substanzen

OsilodrostatHydrocortisoneImidazolesPyridines

Autor:innen und Institutionen

  • Omi Medical Center, Kusatsu 525-8585, Japan.
  • Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR 97239, USA.
  • Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples 80131, Italy.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, South Korea.
  • Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.

Förderung

  • Novartis Pharma AG

Zitieren

APA

Shimatsu, A., Biller, B. M., Fleseriu, M., Pivonello, R., Lee, E. J., Leelawattana, R., Kim, J. H., Walia, R., Yu, Y., Liao, Z., Piacentini, A., Pedroncelli, A. M., & Snyder, P. J. (2024). Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocrine Journal, 71(12), 1103-1123. https://doi.org/10.1507/endocrj.ej24-0153

Vancouver

Shimatsu A, Biller BM, Fleseriu M, Pivonello R, Lee EJ, Leelawattana R, et al. Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocrine Journal. 2024;71(12):1103-1123. doi:10.1507/endocrj.ej24-0153

BibTeX
@article{Shimatsu2024,
  author = {Shimatsu, Akira and Biller, Beverly Mk and Fleseriu, Maria and Pivonello, Rosario and Lee, Eun Jig and Leelawattana, Rattana and Kim, Jung Hee and Walia, Rama and Yu, Yerong and Liao, Zhihong and Piacentini, Andrea and Pedroncelli, Alberto M and Snyder, Peter J},
  title = {Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)},
  journal = {Endocrine Journal},
  year = {2024},
  volume = {71},
  number = {12},
  pages = {1103--1123},
  doi = {10.1507/endocrj.ej24-0153}
}
Kostenlos starten →